MRTX
Mirati Therapeutics Inc
Halal Rating :
Last Price
$58.90
Last updated:
Market Cap
-
7D Change
0.0%
1 Year Change
0.0%
Company Overview
Industries
Exchange
Next Earnings Date
Mirati Therapeutics Inc is a biotechnology company focused on developing novel therapeutics targeting the genetic and immunological drivers of cancer. The company's primary focus is on developing precision medicines for patients with specific genetic mutations. Their lead product candidates include adagrasib (KRAZATI), which targets KRAS G12C mutations in various types of cancer.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2023 | $16.4m | $189.88m | - | - | 0.00% | 0.00% |
| June 30, 2023 | $13.69m | $200.96m | - | - | 0.00% | 0.00% |
| March 31, 2023 | $7.17m | $200.99m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Mirati Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.